Ergothioneine is a compound with demonstrated antioxidant properties that is found in high concentrations in the Grifola Frondosa mushroom. While the therapeutic effects of this substance have been investigated in various conditions related to oxidative stress, studies have not yet explored its role in preventing age-related macular degeneration. This is a progressive condition characterized by central vision loss due to reduction in the retinal pigment epithelium, for which oxidative damage is a significant risk factor. This study will explore whether administration of ergothioneine extract will reduce three major biomarkers of age-related oxidative stress. Ergothioniene will be administered to both wild-type and erythroid 2-related factor 2 knockout mice and compared to two corresponding control groups, for a total of four groups. Treatment will be administered at a dosage of 2 mg/kg body weight daily for 4 weeks. Quantitative autofluorescence, high-performance liquid chromatography with electrochemical detection, and quantitative polymerase chain reaction assay techniques will be utilized to assess biomarkers. One-way analysis of variance will be used to determine statistical significance. This study intends to aid in the development of novel treatment compounds and encourage further explorations into the role of free radicals in various ophthalmological diseases.
Read full abstract